Mouse IL-8 ELISA Kit (MOFI01258)

• Microplate reader with 450 nm wavelength filter
• Multichannel Pipette, Pipette, microcentrifuge tubes and disposable pipette tips
• Incubator
• Deionized or distilled water
• Absorbent paper
• Buffer resevoir

When carrying out an ELISA assay it is important to prepare your samples in order to achieve the best possible results. Below we have a list of procedures for the preparation of samples for different sample types.

Interleukin-8 (IL-8), also known as CXCL8, is a chemokine involved in immune responses and inflammation regulation in various organisms, including mice. IL-8 is produced and secreted by various cell types, such as macrophages, neutrophils, and endothelial cells, in response to inflammatory stimuli. Its primary role is to recruit and activate neutrophils to sites of infection or tissue damage. Understanding IL-8 in mice can provide valuable insights into the mechanisms of inflammation and may offer potential therapeutic targets for related diseases.

The primary function of IL-8 in mice is to recruit and activate neutrophils, a type of white blood cell, to sites of infection or tissue damage. IL-8 acts as a chemoattractant by binding to its specific receptors, CXCR1 and CXCR2, which are expressed on the surface of neutrophils. This binding triggers a cascade of intracellular signaling events that promote neutrophil migration toward the site of inflammation. Additionally, IL-8 also stimulates the release of enzymes and reactive oxygen species by neutrophils, further contributing to the immune response.

The mechanism of action of IL-8 involves the activation of intracellular signaling pathways upon binding to its receptors. Once IL-8 binds to CXCR1 or CXCR2 on the surface of neutrophils, it triggers the activation of various signaling molecules, including G proteins and protein kinases. These signaling cascades lead to changes in cytoskeletal rearrangement, calcium mobilization, and the release of inflammatory mediators, ultimately facilitating neutrophil recruitment and activation.

The clinical significance of IL-8 in mice is well-documented, particularly in the context of inflammatory diseases and infections. Elevated levels of IL-8 have been observed in various mouse models of inflammation, such as arthritis, colitis, and lung injury. Moreover, studies have shown that blocking IL-8 or its receptors can attenuate inflammation and reduce tissue damage in these disease models. In infections, IL-8 plays a crucial role in host defense by recruiting neutrophils to the site of infection, where they can eliminate pathogens. However, dysregulated IL-8 production can contribute to excessive inflammation and tissue damage.

IL-8 inhibitors are substances that specifically target and block the activity of interleukin-8 (IL-8), a chemokine involved in inflammation regulation. Monoclonal antibodies directed against IL-8 or its receptors, CXCR1 and CXCR2, have been developed to disrupt IL-8 signaling pathways. These antibodies aim to impede IL-8-mediated neutrophil recruitment and activation, potentially mitigating excessive inflammation and tissue damage. Small molecule inhibitors that target IL-8 receptors have also been investigated as a means to inhibit IL-8 signaling. These molecules interfere with the binding of IL-8 to its receptors, thus disrupting downstream signaling events. In addition, strategies targeting the production or secretion of IL-8 have been explored, including inhibitors of enzymes and signaling pathways involved in IL-8 synthesis or release. The development of effective IL-8 inhibitors may provide novel therapeutic approaches for modulating immune responses and reducing inflammation.